Skip to main content

For Industry

You are here

Company Profiles

  • Cook Medical Logo

    Cook Medical

    Cook Medical makes 16,000 products that serve 13 hospital lines and provides products to 135 countries.

    Visit Website ]

    Category:Devices

  • VisiSonics Logo

    VisiSonics

    VisiSonics leverages world-class scientific discovery to add a third dimension to the sound you hear electronically, bringing 3D sound to gaming, virtual reality, and entertainment (movies and music) platforms.

    Visit Website ]

    Category:Devices

    Established:

  • Coaptech Logo

    Coaptech

    CoapTech is a seed stage company seeking partners interested in improving medical care delivery for patients young and old around the world.   Their patent-pending, platform technology will be utilized initially to disrupt the market for enteral nutrition feeding tubes.   The CoapTech system will de-skill the procedure for feeding tube placement, offering a simpler, safer, and more affordable method.    

    Visit Website ]

    Category:Devices

    Established:

  • Countervail Corporation

    Countervail Corporation

    Countervail Corporation is  focused on providing protection and treatment of military and civilian populations from exposure to chemical and biological weapons. 

    Visit Website ]

    Category:Biologics

    Established:

  • Pax Vax Logo

    PaxVax

    PaxVax is an independent vaccine company with a robust pipeline that brings to market specialty vaccines that protect against existing and emerging infectious diseases.

    Visit Website ]

    Category:Vaccines

    Established:

  • Otomagnetics Logo

    Otomagnetics, LLC

    A University of Maryland College Park spin-out, is developing a non-invasive method to effectively deliver drugs and other therapeutic payloads to the inner and middle ear.

    Visit Website ]

    Category:Bioengineering

    Established:

  • Archimedes Bioengineering, LLC Logo

    Archimedes Bioengineering, LLC

    Archimedes Bioengineering, LLC is a collaborative effort between University of Maryland, College Park (UMCP), Children’s National Medical Center, and a private company. Archimedes is based on a portfolio of patent pending diagnostic technologies that enable the detection of aminoacidopathy disorders such as, Hyperammonemia, Phenylketonuria (PKU), Maple Syrup Urine Disease, and Aminoacidemia which are a group of metabolic disorders that result from the build-up of one or more amino acids in the blood and/or urine. These metabolic disorders may be caused by defects in enzymatic pathways that inhibit the metabolism of the certain amino acids. Using different diagnostic device designs and embodiments, Archimedes hopes to revolutionize the point-of-care market for aminoacidopathy diagnostics. 

    Visit Website ]

    Category:Bioengineering

    Established:

  • ElectroMed, LLC

    ElectroMed, LLC has licensed the Quick-Release Self-Contained Medical Electrode (US Patent 8,897,853) developed by students at the Fischell Department of Bioengineering. This novel electrode achieves five goals in having increased hydrogel adhesiveness, combining the electrode and adhesive remover in a single unit, greatly reducing removal force required, eliminating leftover residue, and whose removal would not compromise local tissues in sensitive skin situations. These properties make the electrode ideal for burn victims and neonates as it strongly adheres to damaged and growing skin while not injuring delicate skin during removal

    Category:Bioengineering

    Established:

  • Sintact Medication Systems

    Sintact Medical Systems, Inc.

    Sintact Medical Systems, Inc. develops non-resorbable films that separate adjacent organs from adhering to each other after surgery. 

    Visit Website ]

    Category:Biomaterials

    Established:

  • Rakta Therapeutics, Inc.

    Rakta Therapeutics, Inc. has licensed the rights to a series of small molecules for the treatment of leishmaniasis, one of the World Health Organizations neglected tropical diseases. Spread by bites sandflies, the Leshmania protozoan are the cause of the disease. Leishmaniasis affects millions of people worldwide and results in tens of thousands of deaths each year. Previous research at the University of Maryland has identified that Leshmania were unable to synthesize heme, a molecule essential for cellular function. Since these protozoans cannot synthesize heme, the parasitic protozoan must absorb heme from their hosts. Through further collaboration with the University of Maryland, Baltimore, the researchers developed inhibitors of the Leshmania heme transport mechanism. Rakta Therapeutics has licensed these inhibitors with the goal of developing the compounds into effective treatments for leishmaniasis. 

    Category:Small molecules

    Established:

Pages